Sneeden Campbell

R&D

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.